- Newly IPO’d Zymeworks promises to design ‘”best in class” antibody and protein therapeutics.
- Using bioinformatics and computational design, the company is targeting HER2-cancer therapies with ZW25 and ZW33.
- An impressive list of collaborations has potential milestones far above $1 billion.
- Early stage gives plenty of time to keep watch on ZYME.
- We’re not yet committed to buying the stock, but placing it on watch.
To read the full article, click here.